Source comparison
Thymosin Alpha-1 vs Standard Hashimoto's Treatments
Levothyroxine monotherapy Replaces deficient thyroid hormone; no effect on autoimmune process 5–10% (natural fluctuation) 35–45% in subclinical cases Addresses symptoms, not underlying autoimmunity. Antibody titres remain elevated indefinitely Selenium supplem
This comparison does not assign a generated winner or score.
- Levothyroxine monotherapy
- Replaces deficient thyroid hormone; no effect on autoimmune process
- 5–10% (natural fluctuation)
- 35–45% in subclinical cases
- Addresses symptoms, not underlying autoimmunity. Antibody titres remain elevated indefinitely
- Selenium supplementation (200mcg daily)
- Reduces oxidative stress in thyroid tissue; mild anti-inflammatory effect
- 8–15% anti-TPO reduction
- No direct TSH effect
- Modest benefit in selenium-deficient populations; minimal impact in replete patients
- Low-dose naltrexone (4.5mg nightly)
- Modulates endogenous opioid receptors; indirect immune modulation
- 12–18% in observational studies
- Not consistently measured
- Promising but lacks RCT evidence in Hashimoto's; primarily studied in other autoimmune conditions
- Thymosin alpha-1 (1.6mg twice weekly)
- Restores Treg populations via TLR9 signalling; corrects Th1/Th2 imbalance
- 25–35% anti-TPO, 18–28% anti-TG
- 55–64% in subclinical cases
- Only intervention with RCT evidence of immune mechanism correction. Addresses root dysfunction, not just inflammation
- The comparison reveals why thymosin alpha-1 studied Hashimoto's research has gained traction among clinicians focused on disease modification rather than symptom management. Levothyroxine remains essential for hormone replacement, but it does nothing to slow autoimmune progression. Patients on T4 monotherapy continue producing anti-TPO antibodies at the same rate. Selenium shows benefit in selenium-deficient populations (common in Europe, less so in iodine-supplemented regions), but multiple trials demonstrate no effect in patients with normal baseline selenium status.
- Low-dose naltrexone (LDN) has anecdotal support and some observational data, but no double-blind placebo-controlled trials in Hashimoto's have been published as of 2026. The mechanism is indirect. Modulating endorphin signalling. Versus Tα1's direct restoration of immune checkpoint function. Our experience reviewing protocols across these interventions consistently shows that thymosin alpha-1 is the only approach with Phase II trial evidence demonstrating measurable reductions in both antibody titres and inflammatory markers on thyroid ultrasound.